ArticleF1000Research2025
Optimization of Bolus-Tracking Thresholds levels in Cerebral CT Angiography: Influence of Patient Characteristics on contrast enhancement dynamics and radiation dose metrics.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral computed tomography angiography (CTA) is widely used to assess neurovascular disorders, but venous contamination often obscures arteries. Optimizing bolus-tracking thresholds is crucial, yet patient factors influencing contrast dynamics and the value of radiation dose indices in head CTA remain unclear. Objectives: To optimize bolus-tracking thresholds in cerebral CTA by examining patient-related influences on enhancement and radiation metrics. Methods: 126 adults undergoing cerebral CTA were evaluated in this prospective study. Demographics, physiologic parameters, peak enhancement time (PET), peak enhancement attenuation (PEA), and dose indices (CTDIvol, SSDE) were recorded. Linear regression identified predictors of enhancement. Two blinded radiologists graded venous contamination. ROC analysis, including age subgroups, determined the optimal HU threshold. Results: Median age was 55.5 years; 70% were male. PET rose with age (+0.086 s/year, p < 0.001) and was shorter in females (-2.39 s, p = 0.003). PEA increased with threshold (+1.03 HU/unit, p < 0.001). Arterial enhancement was higher in females (+40.7 HU, p < 0.001) and patients ≥60 years (+70 HU, p < 0.001). Venous enhancement correlated with PET (p = 0.023) and systolic pressure (p = 0.002). ROC analysis showed an optimal threshold of 105 ± 5 HU (AUC = 0.634; sensitivity 88.4%, specificity 77.1%). CTDIvol, but not SSDE, correlated with weight (p = 0.015). Conclusion: Intrinsic (age, gender) and extrinsic (threshold) factors shape CTA enhancement. A 105 ± 5 HU threshold reduces venous contamination, especially in younger patients. CTDIvol remains the preferred dose index. Findings support individualized, resource-efficient CTA protocols aligned with UN SDGs 3, 9, and 12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.